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A B S T R A C T
Purpose
Uveal melanoma is the most common primary intraocular malignancy in adults with no effective
systemic treatment option in the metastatic setting. Selumetinib (AZD6244, ARRY-142886) is an
oral, potent, and selective MEK1/2 inhibitor with a short half-life, which demonstrated single-agent
activity in patients with metastatic uveal melanoma in a randomized phase II trial.
Methods
The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
study was a phase III, double-blind trial (ClinicalTrial.gov identiﬁer: NCT01974752) in which patients
with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to
selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-
day cycle) or placebo plus dacarbazine. The primary end point was progression-free survival (PFS) by
blinded independent central radiologic review. Secondary end points included overall survival and
objective response rate.
Results
A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or
placebo plus dacarbazine (n = 32). In the selumetinib plus dacarbazine group, 82 patients (85%)
experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median,
2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32). The
objective response rate was 3% with selumetinib plus dacarbazine and 0% with placebo plus
dacarbazine (two-sided P = .36). At 37% maturity (n = 48 deaths), analysis of overall survival gave
a hazard ratio of 0.75 (95%CI, 0.39 to 1.46; two-sided P= .40). Themost frequently reported adverse
events (selumetinib plus dacarbazine v placebo plus dacarbazine) were nausea (62% v 19%), rash
(57% v 6%), fatigue (44% v 47%), diarrhea (44% v 22%), and peripheral edema (43% v 6%).
Conclusion
In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had
a tolerable safety proﬁle but did not signiﬁcantly improve PFS comparedwith placebo plus dacarbazine.
J Clin Oncol 36:1232-1239. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Uveal melanoma arises from the uveal tract of the
eye, which includes the choroid, ciliary body, and
iris, and is the most common primary intraocular
malignancy in adults.1 Uveal melanoma is bi-
ologically distinct from cutaneous melanoma2 and
accounts for approximately 3% to 5% of all mel-
anomas in the United States. There are currently no
approved or effective systemic therapies speciﬁcally
for these patients.
Mutations in GNAQ or GNA11 are found
in . 80% of uveal melanomas, resulting in con-
stitutive activation of the RAS/RAF/MEK/ERK
(RAS-ERK) pathway.3-5 Selumetinib (AZD6244,
ARRY-142886) is an oral, potent, and highly se-
lective MEK1/2 inhibitor6 that has a short half-life
of approximately 5 hours.7,8 In vitro, selumetinib
plus temozolomide, an oral prodrug of dacarbazine,
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enhanced tumor growth inhibition, DNAdamage, and apoptosis in
a KRAS-mutant colorectal tumor model compared with temo-
zolomide monotherapy.9 In vivo studies demonstrated that selu-
metinib increases the levels of the proapoptotic protein BIM,
a mediator of chemotherapy-induced cell death; therefore, addi-
tion of selumetinib to chemotherapy may increase cytotoxicity
compared with chemotherapy alone.9,10 Clinical trials assessing
efﬁcacy of selumetinib plus chemotherapy have shown activity in
patients with mutations associated with the RAS-ERK pathway.11
In an open-label phase II study, patients with metastatic uveal
melanoma who had not received prior treatment with temozo-
lomide or dacarbazine achieved improved median progression-free
survival (PFS) with selumetinib 75 mg twice daily versus temo-
zolomide or dacarbazine (15.9 v 7 weeks; hazard ratio [HR] 0.46;
95% CI, 0.30 to 0.71; one-sided P , .001).12
Building on this evidence, we initiated a phase III trial to assess
efﬁcacy and safety of selumetinib plus dacarbazine in patients
previously untreated with systemic therapy for metastatic uveal
melanoma (Clinicaltrials.gov identiﬁer: NCT01974752).13
METHODS
Study Design
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic
Uveal Melanoma (SUMIT) was a randomized, international, double-blind,
placebo-controlled, phase III trial in which patients from 29 centers across
11 countries were enrolled (ClinicalTrials.gov identiﬁer: NCT02768766).
The protocol was approved by the local institutional review board or ethics
committee of each participating site. The study was conducted in ac-
cordance with the principles of the Declaration of Helsinki and the Good
Clinical Practice guidelines of the International Conference on Harmo-
nization. All patients gave informed consent before undergoing any study-
speciﬁc procedures.
Patients were randomly assigned 3:1 to receive selumetinib or
matched placebo, plus dacarbazine, stratiﬁed by presence or absence of
liver metastases.
Patients
Patients were eligible if they had histologically or cytologically
conﬁrmed metastatic uveal melanoma, one or more lesions that could be
accurately measured using Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1, and an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 to 1. Patients were excluded if they had previously
received systemic anticancer therapy (prior surgery and intrahepatic or
other nonsystemic therapies were permitted); history of retinal pigmented
epithelial detachment, central serous retinopathy, or retinal vein occlusion
in the unaffected eye; or intraocular pressure. 21 mmHg or uncontrolled
glaucoma (irrespective of intraocular pressure) in the unaffected eye.
Procedures
Patients received selumetinib (75 mg twice daily, continuous oral
administration) or matched placebo, plus dacarbazine (1,000 mg/m2 in-
travenously on day 1 of every 21-day cycle) until objective disease pro-
gression (conﬁrmed by blinded independent central review [BICR]),
intolerable toxicity, or another discontinuation criterion was met. Upon
conﬁrmation of objective disease progression, patients could receive open-
label selumetinib monotherapy or selumetinib plus dacarbazine.
All patients were assessed by computed tomography (CT) scan or
magnetic resonance imaging (MRI) at screening, week 6, and every 6 weeks
thereafter until objective disease progression. Tumor response to treatment
was assessed by BICR using RECIST 1.1.
Adverse events (AEs) were recorded from the time of informed
consent, and graded using the National Cancer Institute Common Ter-
minology Criteria for AEs (version 4.0). Baseline tumor samples from 106
patients were submitted to FoundationMedicine for prospective molecular
proﬁling.
Study End Points
The primary end point was efﬁcacy of selumetinib plus dacarbazine
compared with placebo plus dacarbazine in terms of PFS assessed by BICR
of CT or MRI scans according to RECIST 1.1.14 Secondary end points
included objective response rate (ORR), duration of response, change in
tumor size at week 6, overall survival (OS), safety and tolerability, and
quality of life. Investigative site–based analysis of PFS was performed as
a sensitivity analysis of the primary end point.
Statistical Analysis
Assuming a true PFS HR of 0.46,12 93 PFS events would provide 90%
power to demonstrate a statistically signiﬁcant difference for PFS at a two-
sided signiﬁcance level of 5%. Approximately 128 patients were required
for 3:1 randomization to selumetinib plus dacarbazine (n = 96 patients) or
placebo plus dacarbazine (n = 32 patients) groups to obtain a minimum of
93 PFS events. Additional information on randomization, masking, sta-
tistical analysis, and procedures is given in the Supplemental Data.
RESULTS
Patients
From April 2014 to February 2015, 152 patients were screened
(Fig 1). Twenty-three patients were excluded and 129 were ran-
domly assigned to either to the study treatment with selumetinib
plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32).
Patient demographics were generally balanced between treatment
groups at baseline, with the exception of sex and number of sites of
disease (Table 1).
Efficacy
The primary end point of PFS assessed by BICR was not met.
In the selumetinib plus dacarbazine group, there were 82 events
(85%) compared with 24 (75%) for placebo plus dacarbazine; the
HR for PFS was 0.78 (95% CI: 0.48 to 1.27) with a two-sided
P value of 0.32 (Fig 2A), showing no signiﬁcant beneﬁt of selu-
metinib plus dacarbazine for PFS. Median estimated PFS was
2.8 months in the selumetinib plus dacarbazine group and
1.8 months in the placebo plus dacarbazine group. Median follow-
up for PFS (ie, time from random assignment to death or pro-
gression for patients with an event, and time from random as-
signment to censoring for censored patients) in the selumetinib
plus dacarbazine and placebo plus dacarbazine groups was 2.7 and
1.5 months, respectively. Three- and 6-month PFS rates were 38%
and 10%, respectively, in the selumetinib plus dacarbazine group,
and 26% and 18%, respectively, in the placebo plus dacarbazine
group.
The sensitivity analysis of ascertainment bias (based on in-
vestigational site–based assessment of PFS) was inconsistent with
the primary analysis, showing statistically signiﬁcant improvement
in PFS for selumetinib plus dacarbazine compared with placebo
plus dacarbazine (3.8 v 2.1 months; HR, 0.49; 95% CI, 0.28 to 0.84;
P = .01; Data Supplement). The sensitivity analysis of evaluation
jco.org © 2018 by American Society of Clinical Oncology 1233
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time bias (based on BICR of CT and MRI scans according to
RECIST 1.1) was consistent with the primary analysis (HR, 0.82;
95% CI, 0.51 to 1.33; P = .42). The interaction test assessing
consistency of treatment effect across potential prognostic factors
was statistically signiﬁcant (P = .046; Fig 3), mainly due to ECOG
performance status, where there was a larger treatment effect in
a small subgroup of patients with ECOG performance status of 1
(HR, 0.28; 95% CI, 0.13 to 0.69) compared with ECOG perfor-
mance status of 0 (HR, 1.05; 95% CI, 0.62 to 1.88). This suggests
that patients with a higher tumor burden may have a larger
treatment effect; however, no ﬁrm conclusions can be made be-
cause of the low patient number.
Analysis of the secondary efﬁcacy end points of OS, ORR, and
percentage change in tumor size at week 6 showed no statistically
signiﬁcant differences between treatment groups. Preliminary
analysis of OS (n = 48 deaths; 37% maturity) by log-rank test gave
an HR of 0.75 (95% CI, 0.39 to 1.46; two-sided P = .40; Fig 2B).
Given the results of the primary analysis, additional analysis of OS
with additional events is not planned. ORRwas similar between the
selumetinib plus dacarbazine (n = 3 of 97; 3%) and placebo plus
dacarbazine (n = 0 of 32; 0%) groups (two-sided P = .36). Three
patients achieved partial responses with durations of 43, 56, and
146 days. Target lesion size at week 6 increased in both groups, with
a geometric mean fold change of 1.06 in the selumetinib plus
dacarbazine group and 1.16 in the placebo plus dacarbazine group,
and with a geometric least squares mean ratio 0.94 (95%CI, 0.88 to
1.02; two-sided P = .13). Waterfall plots of best percentage change
in tumor size from baseline for all patients are shown in the Data
Supplement.
At data cutoff, 16 patients (17%) from the selumetinib plus
dacarbazine group and four (13%) from the placebo plus dacar-
bazine group remained on their randomly assigned study arm.
Twenty-three patients (18%) received open-label selumetinib after
disease progressionwhile in the initially assigned study arm (n = 15
with selumetinib monotherapy and n = 8 with selumetinib plus
dacarbazine). The majority of these patients (n = 17 of 23) had
been randomly assigned to placebo plus dacarbazine in the double-
blind phase. Four patients (3%) were receiving ongoing open-label
treatment at the time of data cut off (three patients continued
receiving selumetinib monotherapy and one continued receiving
selumetinib plus dacarbazine). Disease progression was the most
common reason for discontinuation of open-label treatment.
Safety
A summary of AEs is provided in Table 2 and Table 3; AEs of
special interest because of their association with selumetinib are
highlighted in Table 3. Incidence of AEs of special interest was
more frequent with selumetinib plus dacarbazine; however, these
were generally grade 1/2. One patient in the selumetinib plus
Randomly assigned 
(n = 129)
Enrolled 
(N = 152)
Not randomly assigned (n = 23)
Enrolled twice in error (n = 1)
(n = 19)
(n = 3)
Eligibility criteria not fulfilled
Patient decided not to be 
  included in random assignment
Randomly assigned to receive selumetinib plus dacarbazine 
and were included in primary analysis
(n = 97)
Randomly assigned to receive placebo plus dacarbazine 
and were included in primary analysis 
(n = 32)
Receiving study treatment 
   at time of data cutoff 
Receiving selumetinib plus 
dacarbazine
Receiving selumetinib only
Receiving dacarbazine only
(n = 16) (n = 81) (n = 4) (n = 28)
(n = 10)
(n = 7)
(n = 1)
(n = 10)
(n = 2)
(n = 2)
(n = 5)
(n = 1)
(n = 37)
(n = 38)
(n = 9)
(n = 6)
(n = 1)
Not receiving study treatment 
   at time of data cutoff 
Received selumetinib 
subsequently
Received selumetinib plus 
dacarbazine subsequently
Received alternative 
therapy
Received no therapy after 
discontinuation
Receiving study treatment 
at time of data cutoff
Receiving placebo plus 
dacarbazine
Receiving placebo only
Not receiving study treatment 
at time of data cutoff
Received selumetinib 
subsequently
Received selumetinib plus 
dacarbazine subsequently
Received alternative 
therapy
Received no therapy 
after discontinuation
Fig 1. CONSORT diagram. Of the 97 patients randomly assigned to receive the combination of selumetinib and dacarbazine, all received the assigned therapy. At the
time of data cutoff, 16 continued to receive the assigned study treatment and did not meet criteria for discontinuation. Of the 81 patients who did meet criteria for
discontinuation, the subsequent treatment received is listed. Of the 32 patients randomly assigned to receive the combination of placebo and dacarbazine, all received the
assigned therapy. At the time of data cutoff, four continued to receive the study treatment and did not meet criteria for discontinuation. Of the 28 patients who did meet
criteria for discontinuation, the subsequent treatment received is listed. Data cutoff was May 15, 2015.
1234 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Carvajal et al
Downloaded from ascopubs.org by University of Glasgow Library on May 2, 2018 from 130.209.115.082
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
dacarbazine group, who died of uveal melanoma progression, had
grade 5 cardiac failure considered by the investigator to be un-
related to study treatment. Safety and tolerability data from pa-
tients receiving open-label therapy were consistent with the mild to
moderate toxicities observed during the double-blind phase.
Despite the AE rate, most patients could be treated with
single-dose interruptions or reductions. The actual treatment
duration of selumetinib or placebo was within 5 days of the
intended duration in each group (Table 2), and the actual dose
intensity relative to intended dose intensity was . 88% for
selumetinib, placebo, and dacarbazine in both groups despite
dose reductions or interruptions. The longer treatment with
selumetinib was due to longer disease control compared with
placebo. Few AEs led to study drug discontinuation; disease
progression was the main reason for study drug discontinuation
(Table 2).
Molecular Analysis
Prior groups have demonstrated uveal melanoma to be
a disease characterized by a low mutational burden and recurrent
chromosomal alterations15; however, most of this work has been
performed using primary uveal melanoma samples.
Of 106 baseline tumor samples (obtained primarily from
metastatic sites of disease) submitted to Foundation Medicine for
genomic proﬁling, 78 were successfully analyzed. There was
a median of nine mutations per sample (range, two to 21 mu-
tations). We observed mutually exclusive GNAQ or GNA11 mu-
tations in 94% of samples (n = 73 of 78), a frequency higher than
observed in The Cancer Genome Atlas (TCGA) for uveal mela-
noma data set (Data Supplement). All GNA11 (n = 41 of 41), and
most GNAQ mutations (n = 29 of 32) occurred in exon 5; the
remaining GNAQ mutations occurred in exon 4 (n = 2). One
additional patient had a variant of unknown signiﬁcance in GNAQ
(G48L, exon 2).
Comparison of data from TCGA, reanalyzed using VarDict,
showed the most signiﬁcant difference between SUMITand TCGA
analyses was the incidence of BAP1 mutations, with 62.3% and
30.0%mutation rates, respectively (P= .00006). This is reﬂective of
the increased risk for development of metastatic disease in primary
uveal melanomas harboring BAP1 mutations.16 There were no
signiﬁcant differences forGNA11,GNAQ, or SF3B1mutations, nor
for MYC ampliﬁcation. CDKN2A/B deletions, GNAS ampliﬁca-
tion, and TP53mutations were only detected in the SUMIT cohort
and at a low frequency (, 10%). Previous reports have highlighted
recurrent mutations in CYSLTR217 and PLCB4,18 but these were
not assessed in this study.
DISCUSSION
Selumetinib plus dacarbazine did not improve clinical outcomes
for patients with metastatic uveal melanoma compared with
placebo plus dacarbazine. Although the previous phase II trial of
selumetinib monotherapy demonstrated an HR of 0.46 (one-sided
P# .001) for PFS in favor of selumetinib over chemotherapy,12 no
signiﬁcant improvement in PFS was observed with selumetinib
plus dacarbazine over placebo plus dacarbazine (HR, 0.78; two-
sided P = .32) in this study. Fourteen percent of patients achieved
a partial response with selumetinib in the phase II trial,12 whereas
only 3% treated with selumetinib plus dacarbazine achieved
a response in the SUMIT trial.
Results of this study differ from others evaluating selumetinib
plus chemotherapy in other tumor types characterized bymitogen-
activated protein kinase (MAPK) pathway activation, which
demonstrate improved clinical activity with combinatorial therapy
over chemotherapy alone.11,19 These studies also demonstrate how
the various mechanisms of MAPK activation can respond differ-
ently to MAPK inhibition. In a phase II trial of selumetinib plus
dacarbazine versus placebo plus dacarbazine in patients with
BRAF-mutant cutaneous or unknown primary melanoma, median
PFS was 5.6 and 3.0 months, respectively (HR, 0.63; 80% CI, 0.47
to 0.84; one-sided P = .021), with an ORR of 40% versus 26%.11 A
phase II trial of selumetinib plus docetaxel versus placebo plus
docetaxel in patients with KRAS-mutant non–small-cell lung
Table 1. Baseline Characteristics
Characteristic
Selumetinib +
Dacarbazine (n = 97),
No. (%)
Placebo +
Dacarbazine (n = 32),
No. (%)
Sex
Female 42 (43) 19 (59)
Male 55 (57) 13 (41)
Age, years, median (range) 63 (2-86) 58 (42-84)
Race
White 96 (99) 31 (97)
Other 1 (1) 1 (3)
ECOG PS
0 72 (74) 22 (69)
1 25 (26) 10 (31)
Primary tumor location
Choroid 86 (89) 29 (91)
Ciliary body 7 (7) 4 (13)
Iris 1 (1) 0
Missing 3 (3) 0
Presence of livermetastases*
Yes 89 (92) 30 (94)
No 8 (8) 2 (6)
Number of organ sites
involved with disease
1 53 (55) 11 (34)
2 20 (21) 9 (28)
3 18 (19) 9 (28)
4 6 (6) 1 (3)
$ 5 0 2 (6)
Time from primary tumor
diagnosis to random
assignment
# 18 months 26 (27) 7 (22)
. 18 to # 36 months 28 (29) 6 (19)
. 36 months 43 (44) 18 (56)
Missing 0 1 (3)
Mutation status† (n = 60) (n = 18)
GNAQ mutation positive 23 (38) 9 (50)
GNA11 mutation positive 33 (55) 8 (44)
GNAQ andGNA11mutation
negative
4 (7) 1 (6)
NOTE. Population: full analysis set, data cutoff: May 15, 2015.
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance
status.
*Stratiﬁcation factor.
†Tumor tissue samples from 106 patients were submitted to Foundation
Medicine for genomic proﬁling: 78 were successfully analyzed; tumor material
was insufﬁcient for testing for 28 patients; samples were not available from 23
patients.
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cancer demonstrated a median PFS of 5.3 versus 2.1 months,
respectively (HR for progression, 0.58, 80% CI, 0.42 to 0.79; one-
sided P = .014), with an ORR of 37% versus 0%.19 However, more
recently, selumetinib plus docetaxel failed to meet the primary end
point of PFS in the phase III SELECT-1 trial.20
Effects of GNAQ and GNA11 mutations on downstream
growth pathways differ from those associated with BRAF and
KRAS mutations, and include activation of the MAPK pathway21
via phospholipase C22 and protein kinase C activation,23 the
phosphatidylinositol-3 kinase (PI3K)/AKT pathway,24 and the
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Fig 2. Kaplan-Meier estimates of progression-free survival and overall survival. (A) Blinded independent central review of progression-free survival. (B) Overall survival.
Population: full analysis set, data cutoff: May 15, 2015. Crosses denote censored observations. Overall survival data are immature, with 34 events (35%) and 14 events
(44%) in the selumetinib plus dacarbazine and placebo plus dacarbazine groups, respectively. DTIC, dacarbazine; HR, hazard ratio; Pbo, placebo; Sel, selumetinib.
Pbo +
DTIC, No. (%)
24/32 (75)
24/30 (80)
0/2 (0)
16/22 (73)
8/10 (80)
6/8 (75)
2/3 (67)
7/9 (78)
9/12 (75)
12/13 (92)
12/19 (63)
15/20 (75)
9/12 (75)
5/8 (62)
9/9 (100)
10/15 (66)
All Patients
Liver metastases at random assignment
Yes
No (n.c.)
Baseline ECOG PS
0
1
Histology/tumor grade
Spindle (n.c.)
Epithelioid
Mixed
Unknown
Sex
Male
Female
Age at random assignment, years
< 65
≥ 65
Biomarker
GNA11 positive
GNAQ positive
Other
PFS Events
Selumetinib +
DTIC, No. (%)
82/97 (85)
75/89 (84)
7/8 (88)
61/72 (85)
21/25 (84)
7/8 (88)
18/21 (86)
13/14 (93)
44/54 (82)
47/55 (86)
35/42 (83)
43/51 (84)
39/46 (85)
27/33 (82)
20/23 (86)
35/41 (86)
HR (selumetinib + DTIC: Pbo + DTIC) and 95% CI
Global Interaction Test P = .046
0 1 2 3 4
HR (95% CI)
0.80 (0.51 to 1.29) 
0.70 (0.45 to 1.14)
1.05 (0.62 to 1.88)
0.28 (0.13 to 0.69)
0.46 (0.13 to 2.92)
0.96 (0.39 to 2.55)
0.58 (0.30 to 1.27)
0.58 (0.32 to 1.15)
0.92 (0.49 to 1.86)
0.83 (0.47 to 1.55)
0.80 (0.41 to 1.77)
1.28 (0.52 to 3.84)
0.51 (0.24 to 1.18)
0.88 (0.45 to 1.87)
Fig 3. Progression-free survival by prespeciﬁed subgroup. Population: full analysis set, data cutoff: May 15, 2015. Hazard ratios were not calculated for subgroups with
, 20 events. With the exception of liver metastases at randomization (yes/no), all analyses were performed using a Cox proportional hazardsmodel. The size of the circle is
proportional to the number of events. Progression includes deaths in the absence of RECIST progression. Progression events occurring 14 weeks after last evaluable
assessment (or randomization) are censored and, therefore, excluded. DTIC, dacarbazine; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard
ratio; n.c., not calculated; Pbo, placebo.
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Hippo pathway.25 This, as well as other cell context–dependent
differences between uveal melanoma, BRAF-mutant cutaneous
melanoma, and KRAS-mutant non–small-cell lung cancer, in part
may explain the discrepant results observed in these trials; however,
additional investigation into these differences is needed. Limited
work conducted in parallel to the SUMIT trial in three xenograft
models derived from patients with uveal melanoma, derived from
metastatic tumor specimens and characterized by GNAQ and
GNA11 mutations, demonstrated that dacarbazine alone and in
combination with selumetinib induced strong tumor growth in-
hibition in one model, and selumetinib continued after combi-
nation treatment signiﬁcantly delayed disease progression
compared with dacarbazine maintenance. However, combination
of selumetinib and dacarbazine did not increase tumor response in
these models compared with either agent alone, comparable to the
results observed in the SUMIT trial.26 These xenograft models derived
from patients with uveal melanoma were difﬁcult to generate;
therefore, these data were not available at the time of trial design.
Median PFS in this study was 2.8 months in the selumetinib
plus dacarbazine group, numerically but not statistically greater
than the 1.8 month median PFS observed in the placebo plus
dacarbazine group. Given the 6-week interval for restaging studies
in this trial, these results are comparable to the PFS of 3.6 months
observed in the selumetinib monotherapy group and 1.6 months
observed in the chemotherapy group in the phase II monotherapy
trial, during which imaging was performed every 4 weeks for
8 weeks, and every 8 weeks thereafter. It was hypothesized that the
lack of signiﬁcant beneﬁt for selumetinib plus dacarbazine in this
study may have been caused by increased toxicity, decreased com-
pliance, or decreased dose density. However, the actual treatment
duration for selumetinib or placebo being within 5 days of the
intended treatment duration in each group, and the actual dose
intensity relative to intended dose intensity . 88% for each treat-
ment across both groups, provides evidence against this hypothesis.
The modest improvement in PFS observed with selumetinib
alone or plus dacarbazine in uveal melanoma suggests that any
clinical activity of MEK inhibitors in G-protein–driven tumors may
be limited by the rapid development of adaptive resistance to MEK
inhibition or progression of primarily resistant tumor clones. This
hypothesis is supported by the results of the phase III trial of
binimetinib, an oral selective adenosine triphosphate–uncompetitive
inhibitor of MEK1/2 versus dacarbazine inNRAS-mutant cutaneous
melanoma, where, despite an overall response rate of 15% with
binimetinib, demonstrating objective radiographic evidence of an-
titumor activity, only a modest improvement in median PFS of 2.8
versus 1.5 months in favor of binimetinib was reported (HR, 0.62;
95% CI, 0.47 to 0.80; P # .001).27
Radiographic assessment of treatment response in liver me-
tastases is associated with unique challenges, with interobserver
agreement dependent on radiologist experience and the imaging
modality used.28 These challenges are ampliﬁed in uveal melanoma,
a disease with a predilection for hepatic metastasis and associated
with greater radiographic heterogeneity compared with other tumor
types as a result of the presence of hemorrhage, methemoglobin, and
melanin.29 These factors may have contributed to the discordance in
our results based on central and site-based radiologic reviews. Al-
though the HR for the primary analysis of PFS assessed by BICR was
a statistically insigniﬁcant 0.78 in favor of selumetinib plus dacar-
bazine (two-sided P = .32), the HR of PFS assessed by investigative
site–based review was 0.49 in favor of selumetinib plus dacarbazine
(two-sided P = .01), with a median PFS of 3.8 versus 2.1 months in
the selumetinib plus dacarbazine and placebo plus dacarbazine
groups, respectively. In 88 of the 106 patients (83%) with PFS events,
there was concordance between central and site-based imaging reviews
regarding the development of disease progression; however, a differ-
ence was observed in the timing of progression events, which was the
primary driver in the difference in PFS as determined by central and
site-based reviews. Despite the double-blinded study design and the
use of independent reference radiologists for review of imaging studies
at most of the participating centers, the distinct toxicity proﬁle as-
sociated with selumetinib that includes easily observable toxicities such
as rash, peripheral edema, and creatine phosphokinase elevation may
have introduced bias into the site-based determination of PFS.
In conclusion, selumetinib plus dacarbazine was not as-
sociated with a signiﬁcant improvement in PFS or ORR for
patients with metastatic uveal melanoma compared with pla-
cebo plus dacarbazine. Given the lack of effective treatment
options for patients with advanced uveal melanoma, rapid
development and testing of novel therapeutic strategies are
critical. The SUMIT trial began 6 years after initial reports of
frequent, functionally activating GNAQ mutations in uveal
melanoma and demonstrates feasibility of the rapid conduct of
pivotal clinical trials in this rare tumor type. Despite the results of
this study, additional assessment of MEK inhibitors in uveal
Table 2. Adverse Events During Randomized Treatment
Category
Selumetinib +
Dacarbazine (n = 97)
Placebo +
Dacarbazine (n = 32)
Any AE 97 (100) 32 (100)
Any AE CTCAE $ grade 3 61 (63) 17 (53)
Any SAE 20 (21) 2 (6)
Any AE leading to
hospitalization
17 (18) 2 (6)
Any AE with outcome of
death
1 (1)* 0
Selumetinib/placebo
Any AE leading to
discontinuation
6 (6)† 1 (3)‡
Any AE leading to dose
interruption
35 (36) 7 (22)
Any AE leading to dose
reduction
20 (21) 4 (13)
Duration of treatment, days,
median (range)§
112 (21-400) 68 (8-418)
Dacarbazine
Any AE leading to
discontinuation
7 (7) 2 (6)
Any AE leading to dose
delay
20 (21) 11 (34)
Any AE leading to dose
reduction
28 (29) 11 (34)
No. of cycles, median
(range)§
5 (1-17) 3 (1-8)
NOTE. Data given as no. (%) unless otherwise indicated. Population: safety
analysis set, data cutoff: May 15, 2015.§
Abbreviations: AE, adverse event; CTCAE, common terminology criteria for
adverse events; SAE, serious adverse event.
*Grade 5 cardiac failure considered unrelated to treatment.
†Retinal vein occlusions (n = 2); blood creatinine phosphokinase increased
(n = 1); febrile neutropenia (n = 1); cardiac failure (n = 1); peripheral edema (n = 1);
lung infection (n = 1).
‡Blood bilirubin increased and hypoalbuminemia (n = 1).
§Treatment summaries as of addendum data cutoff: February 18, 2016.
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melanoma is warranted. It remains a possibility that dacarbazine limits
the efﬁcacy of MEK inhibitors in this disease, and the exploration
selumetinib as monotherapy or in alternative combinations, other
than with alkylating agents, remains of interest. A trial evaluating
selumetinib plus paclitaxel for metastatic uveal melanoma is underway
(EudraCT: 2014-004437-22). On the basis of the hypotheses that
greater efﬁcacy and improved tolerability may be achieved by de-
livering selumetinib in greater doses, with more complete target in-
hibition using a pulsatile dosing schedule, a phase Ib dose-escalation
study of intermittent selumetinib in patients with advanced uveal
melanomawho have not been previously treated with aMEK inhibitor
is also ongoing (ClinicalTrials.gov: NCT02768766).
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Table 3. Most Frequent Adverse Events (All Causality) Reported in $ 10% of Patients During Randomized Treatment
Preferred Term
Selumetinib + Dacarbazine (n = 97), No. (%) Placebo + Dacarbazine (n = 32) , No. (%)
Any Grade Grade 3 Grade 4 Any Grade Grade 3 Grade 4
Nonlaboratory parameters
Patient with any adverse event 97 (100) 47 (48) 13 (13) 32 (100) 10 (31) 7 (22)
Nausea* 60 (62) 1 (1) 0 6 (19) 0 0
Rash* 55 (57) 2 (2) 0 2 (6) 0 0
Fatigue* 43 (44) 1 (1) 0 15 (47) 2 (6) 0
Diarrhea* 43 (44) 2 (2) 0 7 (22) 0 0
Peripheral edema* 42 (43) 2 (2) 0 2 (6) 0 0
Constipation 37 (38) 1 (1) 0 14 (44) 0 0
Dermatitis acneiform* 30 (31) 1 (1) 0 1 (3) 0 0
Vomiting* 27 (28) 1 (1) 0 6 (19) 0 0
Asthenia 21 (22) 2 (2) 0 4 (13) 0 0
Dyspnea 19 (20) 0 0 3 (9) 0 0
Hypertension* 18 (19) 8 (8) 0 1 (3) 1 (3) 0
Decreased appetite 17 (18) 1 (1) 0 9 (28) 0 0
Anemia 17 (18) 1 (1) 0 4 (13) 1 (3) 0
Stomatitis* 15 (16) 0 0 2 (6) 0 0
Pruritus 14 (14) 0 0 3 (9) 0 0
Headache 13 (13) 2 (2) 0 3 (9) 1 (3) 0
Myalgia 12 (12) 0 0 1 (3) 0 0
Skin ﬁssures 12 (12) 0 0 0 0 0
Urinary tract infection 11 (11) 1 (1) 0 4 (13) 1 (3) 0
Dysgeusia 11 (11) 0 0 3 (9) 0 0
Dyspepsia 11 (11) 0 0 2 (6) 0 0
Dry skin* 11 (11) 0 0 0 0 0
Abdominal pain 10 (10) 1 (1) 0 3 (9) 1 (3) 0
Vision blurred* 10 (10) 0 0 1 (3) 0 0
Pyrexia* 9 (9) 0 0 5 (16) 0 0
Insomnia 7 (7) 0 0 4 (13) 0 0
Arthralgia 5 (5) 0 0 4 (13) 0 0
Laboratory parameters†
Blood creatinine phosphokinase level increased*‡ 36 (37) 8 (8) 2 (2) 2 (6) 0 0
Aspartate aminotransferase level increased 28 (29) 6 (6) 0 5 (16) 1 (3) 0
Alanine aminotransferase level increased 27 (28) 6 (6) 1 (1) 5 (16) 2 (6) 0
Thrombocytopenia 26 (27) 8 (8) 4 (4) 4 (13) 0 0
Neutropenia 25 (26) 12 (12) 7 (7) 11 (34) 3 (9) 7 (22)
Note. Population: safety analysis set, data cutoff: May 15, 2015. Adverse events reported in$ 10%patients, ordered by frequency in patients receiving selumetinib plus
dacarbazine.
*Adverse event of special interest because of known association with selumetinib.
†Deterioration compared with baseline in protocol-mandated laboratory values were reported as adverse events if they fulﬁlled any of the serious adverse event criteria
or were the reason for discontinuation of treatment with the investigational product.
‡Creatinine phosphokinase increase was prospectively measured in the battery of laboratory parameters.
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